The short version
Just 2 companies supply this market — thin enough that a single exit would be felt immediately.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Vyalev
foscarbidopa/foslevodopa · FOSCARBIDOPA 12 mg/mL; FOSLEVODOPA 240 mg/mL · Injection · Subcutaneous · AbbVie Inc.
NDC 00074-0501-01 · 7 VIAL, SINGLE-DOSE in 1 CARTON / 10 mL in 1 VIAL, SINGLE-DOSE · NDA · View full market →
One drug, every price
The same NDC has different prices depending on who is paying. Units differ between rungs — compare within a rung over time, not rung against rung, unless the units match.
ⓘ How this was built
Data sources
- CMS NADAC (pharmacy acquisition, weekly)
- CMS Part B ASP quarterly payment limits
- CMS Maximum Fair Prices (IRA negotiated, NDC-level)
- Medicare Part D Spending by Drug (data.cms.gov, name-matched)
- VA FSS / Big4 federal contract prices (va.gov, twice monthly)
- ACA Federal Upper Limits + weighted AMP (data.medicaid.gov, monthly)
- California SB-17 WAC filings (list price, per package)
Method
Each rung is the newest figure for this NDC from one federal price system, shown with its own unit. Part D is matched by drug name because CMS publishes no NDCs there; it is gross spending, before confidential rebates.
Pipeline and calculations built by Claude (Fable 5) from the public datasets above. Educational only — verify against primary sources before acting.
- Medicare Part B pays (ASP+6%)$0.7020per billing unit (0.25 MG - 5 MG)HCPCS J7356 · Jul 1, 2026
- Federal ceiling (Big4)$1,719.94per package of 7X10MLAbbvie US LLC · Jan 1, 2026
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Estimated fill cost
WAC per package, as filed
$2,292.64
Reported to Texas DSHS · 2026 annual filing · Abbvie Inc
Manufacturer list price as filed — not what pharmacies actually pay after discounts.
Medicare Part B (ASP)
Payment limit per 0.25 MG - 5 MG
$0.702
HCPCS J7356 · Jul 1, 2026 quarter · typically ASP + 6%
Medicaid spend (2025)
$478,615
68 prescriptions paid by Medicaid nationally · all Medicaid spend →
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Is this a "specialty" drug?
There's no legal definition — it meets 1 of 6 public criteria. Why that matters →
- Part D specialty tier
- Costs ≥ $950/fill
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program
Regulatory
- Application
- NDA216962
- TE code
- —
- Approval date
- Oct 16, 2024
- Patents / exclusivity
- 4 patents, 1 exclusivities
| Type | Number / code | Expires |
|---|---|---|
| exclusivity | NP | Oct 16, 2027 |
| patent | 12251365 | Jun 10, 2040 |
| patent | 9446059 | Oct 21, 2035 |
| patent | 10174061 | Oct 21, 2035 |
| patent | 10730895 | Oct 21, 2035 |
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of foscarbidopa/foslevodopa (Injection)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Patheon Manufacturing Services LLC | FOSLEVODOPA 240 mg/mL; FOSCARBIDOPA 12 mg/mL | Aug 20, 2026 | Sep 3, 2026 |
| AbbVie Inc. | FOSCARBIDOPA 12 mg/mL; FOSLEVODOPA 240 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
| Patheon Manufacturing Services LLC | FOSLEVODOPA 12 mg/mL; FOSCARBIDOPA 240 mg/mL | Jul 22, 2026 | Aug 19, 2026 |
| Patheon Manufacturing Services LLC | FOSCARBIDOPA 12 mg/mL; FOSLEVODOPA 240 mg/mL | Jul 15, 2026 | Jul 15, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Vyalev — NDC 00074-0501-01," retrieved September 3, 2026, https://drugdashboards.com/drug/00074050101.
Free to cite with attribution — see how the data is put together.